Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211726 | 0.88 | NPY2R (0.49) | NPY2RTP53OPRK1POLBTBK1 | |
| Hydrochloric Acid SCHEMBL5216190 | 0.87 | NPY2R (0.49) | NPY2RTP53OPRK1POLBTBK1 | |
| SCHEMBL4031576 | 0.83 | ACHE (0.41) | TP53OPRK1OPRM1KCNH2PIK3CD | |
| SCHEMBL4032284 | 0.80 | OPRK1 (0.44) | OPRK1OPRM1PIK3CDPIK3CG | |
| SCHEMBL4666781 | 0.79 | NPY2R (0.51) | NPY2RTP53POLBTBK1 | |
| SCHEMBL354519 | 0.76 | NPY2R (0.52) | NPY2RTP53POLBTBK1 | |
| Hydrochloric Acid SCHEMBL355157 | 0.75 | NPY2R (0.52) | NPY2RTP53POLBTBK1 | |
| SCHEMBL4033859 | 0.74 | CNR2 (0.41) | OPRK1OPRM1PIK3CDPIK3CG | |
| SCHEMBL4034511 | 0.71 | USP7 (0.45) | TP53OPRK1KCNH2 | |
| SCHEMBL353983 | 0.71 | NPY2R (0.79) | NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | claimed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| US-7638631-B2 | Methylene dipiperidine derivatives | GLAXO GROUP LIMITED (GB) | 2009-12-29 | — | — | US | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| EP-1789410-B1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | GLAXO GROUP LIMITED (GB) | 2008-05-08 | — | — | US | disclosed |
| EP-1789410-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029906-A1 | METHYLENE DIPIPERIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108624-A1 | Methylene Dipiperidine Derivatives | DRD2, DRD4, PNMT | NPY2R 410/4885TP53 4824/4885OPRK1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.